XML 29 R48.htm IDEA: XBRL DOCUMENT v3.20.1
SEGMENT INFORMATION (Tables)
12 Months Ended
Dec. 31, 2019
SEGMENT INFORMATION  
Schedule of segment information

Segment information for the years ended and as of December 31, 2019 and December 31, 2018 are as follows:

​

​

​

​

​

​

​

​

​

    

Biopharmaceutical

    

Biomaterial

    

​

​

​

Products

​

Products

​

Total

​

​

USD

​

USD

​

USD

Year ended December 31, 2019

 

  

 

  

 

  

Sales

 

457,738,968

 

46,005,954

 

503,744,922

Cost of sales

 

170,119,887

 

4,546,657

 

174,666,544

Gross profit

 

287,619,081

 

41,459,297

 

329,078,378

Income from operations

 

146,889,589

 

16,758,294

 

163,647,883

Net income

 

138,237,792

 

25,157,394

 

163,395,186

Equity in income of an equity method investee

 

1,587,067

 

—

 

1,587,067

Interest income

 

21,292,269

 

29,970

 

21,322,239

Share-based compensation

 

26,600,015

 

—

 

26,600,015

Depreciation and Amortization

 

17,729,392

 

8,511,479

 

26,240,871

​

​

​

​

​

​

​

Segment assets

 

2,195,660,575

 

368,932,329

 

2,564,592,904

Capital expenditures

 

22,966,579

 

3,826,444

 

26,793,023

Equity method investment

 

16,725,513

 

—

 

16,725,513

​

​

​

​

​

​

​

​

​

    

Biopharmaceutical 

    

Biomaterial 

    

​

​

​

Products

​

Products

​

Total

​

​

USD

​

USD

​

USD

Year ended December 31, 2018

​

  

​

  

​

  

Sales

​

422,166,244

​

44,711,325

​

466,877,569

Cost of sales

​

141,683,089

​

5,104,147

​

146,787,236

Gross profit

​

280,483,155

​

39,607,178

​

320,090,333

Income from operations

 

128,980,355

 

17,192,396

 

146,172,751

Net income

 

131,561,108

 

16,406,007

 

147,967,115

Equity in income of an equity method investee

 

2,368,995

 

—

 

2,368,995

Interest income

 

13,704,954

 

1,796

 

13,706,750

Share-based compensation

 

23,130,570

 

—

 

23,130,570

Depreciation and Amortization

 

13,902,507

 

9,322,844

 

23,225,351

Income tax expense

 

15,353,208

 

2,682,972

 

18,036,180

​

​

​

​

​

​

​

Segment assets

 

2,095,996,321

 

348,885,628

 

2,444,881,949

Capital expenditures

 

35,245,016

 

1,471,374

 

36,716,390

Equity method investment

 

15,428,028

 

—

 

15,428,028

Schedule of reconciliation of segment assets to consolidated total assets

Reconciliation of segment assets to consolidated total assets:

​

​

​

​

​

​

​

    

December 31, 

 

December 31, 

​

​

2019

 

2018

​

​

USD

 

USD

Total segment assets

 

2,564,592,904

​

2,444,881,949

Elimination of intercompany investment balances

 

(626,734,407)

​

(434,903,268)

Consolidated total assets

 

1,937,858,497

​

2,009,978,681